MSC therapy for diabetic kidney disease and nephrotic syndrome
Nature Reviews Nephrology, Published online: 02 October 2023; doi:10.1038/s41581-023-00776-zNew clinical studies suggest that mesenchymal stem cell (MSC) therapy can have positive clinical effects, potentially via immunomodulation, in patients with diabetic nephropathy or nephrotic syndrome. These trials suggest that the therapy is safe, but adverse reactions highlight the need to examine the source and functional attributes of MSCs closely.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Bo Lu Lilach O. Lerman Source Type: research
More News: Diabetes | Endocrinology | Nephrotic Syndrome | Stem Cell Therapy | Stem Cells | Study | Urology & Nephrology